RDPAC representing 46 leading multinational pharmaceutical companies with R&D capabilities, is a committee under the China Association of Enterprises with Foreign Investment (CAEFI), which in turn reports to the Ministry of Commerce of the People's Republic of China.

OVERVIEW

Established in 1999, the R&D-Based Pharmaceutical Association Committee (RDPAC), representing 46 leading multinational pharmaceutical companies with R&D capabilities, is a committee under the China Association of Enterprises with Foreign Investment (CAEFI), which in turn reports to the Ministry of Commerce of the People's Republic of China.

As of June 2020, RDPAC member companies have established 47 manufacturing facilities and 25 R&D centers in mainland China. From 1999 to 2021, RDPAC member companies have introduced more than 760 innovative drugs to China market.

VISION

HEALTHIER CHINA THROUGH INNOVATION

To be a valued partner in delivering the “Healthy China” goal to improve the health and quality of life of people in China:
•      Provide high-quality/ innovative healthcare products and services in a socially responsible and commercially viable manner;
•      Commit to securing patients timely access to innovative & high quality drugs;
•      Achieve the highest standard of integrity for ethical research and business practice;
•      Contribute to the growth of the biopharmaceutical sector in China;
•      Support the development of a sustainable healthcare system in China.

RDPAC Executive Committee（2022-2023）

MEMBERSHIP

Note: the Executive Committee and the member companies are listed in alphabetical order according to the English names of the member companies.

RDPAC CODE

A major requisite for innovation is integrity, which is also the foundation of reputation. Without ethical decision-making, there is no true innovation.

As the first pharmaceutical industry organization in China to attach great importance to compliance, and as a member and an active player of the global pharmaceutical industry association network, RDPAC has continuously strived to reflect the latest standards of international pharmaceutical industry associations, using the Code of Practice of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) as its foundation in doing so. At the same time, RDPAC has kept abreast of the latest requirements of Chinese laws, regulations and policies, and the cutting-edge developments in business practices and compliance controls in China's pharmaceutical industry, providing member companies with the latest and highest standards of compliance based on best practice. Adherence to the RDPAC Code of Practice has also been made a precondition for companies to join RDPAC. Furthermore, RDPAC is supportive of the member companies’ intention to develop and implement their more stringent in-house codes of practice on this basis.

DOWNLOAD

MRC